INFAI

Executive Summary

INFAI is a German diagnostics company with over 25 years of expertise in non-invasive, stable isotope-based breath tests. Its flagship product, the Helicobacter Test INFAI, is a ¹³C-urea breath test widely used for detecting Helicobacter pylori infection, offering a reliable alternative to invasive procedures like endoscopy. The company also provides tests for gastrointestinal function (e.g., gastric emptying), cardiovascular risk assessment, and inborn metabolic disorders, leveraging advanced technologies such as isotope ratio mass spectrometry (IRMS) and nuclear magnetic resonance (NMR) spectroscopy. With a strong presence in Europe, INFAI has built a reputation for high-quality, non-invasive diagnostic solutions. As a mature private company founded in 1998, INFAI is well-positioned for growth through geographic expansion and new product development. The global demand for non-invasive diagnostics is rising, and INFAI's proven technology platform could address unmet needs in emerging markets. Potential catalysts include regulatory approvals for new breath tests (e.g., for liver function or fat malabsorption), strategic partnerships to expand distribution, and entry into high-growth regions such as Asia. While financial details are limited, INFAI's established product portfolio and specialized expertise suggest a stable outlook with moderate upside potential.

Upcoming Catalysts (preview)

• Q3 2026Regulatory approval for a new breath test (e.g., liver function or fat malabsorption) in Europe60% success
• Q4 2026Partnership with a global diagnostics distributor to enter Asian markets50% success
• Q2 2026Positive clinical study results for an expanded indication of its Helicobacter Test40% success